BRPI0411831A - métodos de inibição da permeabilidade vascular e apoptose - Google Patents

métodos de inibição da permeabilidade vascular e apoptose

Info

Publication number
BRPI0411831A
BRPI0411831A BRPI0411831-6A BRPI0411831A BRPI0411831A BR PI0411831 A BRPI0411831 A BR PI0411831A BR PI0411831 A BRPI0411831 A BR PI0411831A BR PI0411831 A BRPI0411831 A BR PI0411831A
Authority
BR
Brazil
Prior art keywords
sphingosine
methods
vascular endothelial
vascular permeability
apoptosis
Prior art date
Application number
BRPI0411831-6A
Other languages
English (en)
Inventor
Timothy Hla
Teresa Sanchez
Ji-Hye Paik
Kevin P Claffey
Original Assignee
Univ Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut filed Critical Univ Connecticut
Publication of BRPI0411831A publication Critical patent/BRPI0411831A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODOS DE INIBIçãO DA PERMEABILIDADE VASCULAR E APOPTOSE". Prevêem o agonista dos receptores de esfingosina-1-fosfato endotelial vascular; compostos como FTY720 podem ser fosforilados por cinase-2 esfingosina para as formas fosforiladas que servem como agonistas do receptor de esfingosina-1-fosfato; os agonistas dos receptores de esfingosina-1-fosfato endotelial vascular são empregados em métodos de tratamento de distúrbios de permeabilidade vascular e apoptose de célula endotelial vascular indesejada em um mamífero e para o crescimento de novos vasos sanguíneos; os agonistas dos receptores de esfingosina-1-fosfato endotelial vascular podem ser usados para a fabricação de um medicamento para tratamento de distúrbios de permeabilidade vascular e apoptose de célula endotelial vascular indesejada e para o crescimento de novos vasos sanguíneos.
BRPI0411831-6A 2003-06-24 2004-06-18 métodos de inibição da permeabilidade vascular e apoptose BRPI0411831A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48223403P 2003-06-24 2003-06-24
PCT/US2004/019420 WO2005002559A2 (en) 2003-06-24 2004-06-18 Methods of inhibiting vascular permeability and apoptosis

Publications (1)

Publication Number Publication Date
BRPI0411831A true BRPI0411831A (pt) 2006-08-08

Family

ID=33563841

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411831-6A BRPI0411831A (pt) 2003-06-24 2004-06-18 métodos de inibição da permeabilidade vascular e apoptose

Country Status (14)

Country Link
US (3) US7838562B2 (pt)
EP (1) EP1643983B1 (pt)
JP (2) JP2007523858A (pt)
CN (2) CN101518524A (pt)
AT (1) ATE466572T1 (pt)
AU (1) AU2004253473B2 (pt)
BR (1) BRPI0411831A (pt)
CA (3) CA2529318C (pt)
DE (1) DE602004027045D1 (pt)
ES (1) ES2342396T3 (pt)
MX (1) MXPA05014216A (pt)
PL (1) PL1643983T3 (pt)
PT (1) PT1643983E (pt)
WO (1) WO2005002559A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014662A1 (en) 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
US20080279897A1 (en) * 2005-01-21 2008-11-13 Medvet Science Pty. Ltd. Method of Treating Cellular Damage
KR100773765B1 (ko) 2005-11-24 2007-11-12 재단법인서울대학교산학협력재단 개선된 스핑고신 유사체의 제조 방법
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
CN102579387A (zh) * 2006-09-26 2012-07-18 诺瓦提斯公司 包含s1p调节剂的药物组合物
SI2083811T1 (sl) 2006-11-22 2017-02-28 Clinical Research Associates, Llc Postopki zdravljenja Downovega sindroma, sindroma krhkega X in avtizma
EP3733161A1 (en) 2007-10-12 2020-11-04 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
CN102464590B (zh) * 2010-11-18 2013-10-23 中国科学院上海药物研究所 一类免疫调节剂及其制备方法和用途
ES2388273B1 (es) * 2011-03-16 2013-10-01 Consejo Superior De Investigaciones Científicas (Csic) Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
EP2831072B1 (en) 2012-03-26 2017-04-19 Arroyo BioSciences L.L.C. Novel sphingosine 1-phosphate receptor antagonists
US9220706B2 (en) * 2012-06-01 2015-12-29 National Institutes Of Health (Nih) Inhibition of leukemic stem cells by PP2A activating agents
WO2014043334A1 (en) * 2012-09-12 2014-03-20 Oklahoma Medical Research Foundation Modulation of podoplanin mediated platelet activation
WO2014175287A1 (ja) * 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
WO2016035769A1 (ja) * 2014-09-01 2016-03-10 パスロジ株式会社 ユーザ認証方法及びこれを実現するためのシステム
WO2016115092A1 (en) * 2015-01-12 2016-07-21 La Jolla Institute For Allergy And Immunology Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
US10111841B2 (en) 2015-06-19 2018-10-30 University Of South Florida Stabilization of alcohol intoxication-induced cardiovascular instability
CN105395530A (zh) * 2015-11-27 2016-03-16 天津医科大学总医院 芬戈莫德的新用途
CN105640928A (zh) * 2016-02-26 2016-06-08 南京医科大学 Fty720在制备预防与治疗缺血性脑卒药物中的应用
CN115120724A (zh) * 2017-05-22 2022-09-30 北京蔚蓝之源医药科技有限公司 治疗再生障碍性贫血的方法和药物组合物
KR20200116953A (ko) * 2018-02-02 2020-10-13 고쿠리츠 다이가쿠 호진 교토 다이가쿠 안내 혈관 신생 및/또는 안내 혈관 투과성 항진을 수반하는 안과 질환의 예방 또는 치료를 위한 의약
EP3677259A1 (en) * 2019-01-07 2020-07-08 Mosaiques Diagnostics And Therapeutics AG Use of arachidonyl trifluoromethyl ketone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503749A (ja) * 1993-07-23 1997-04-15 エルエックスアール バイオテクノロジー インコーポレイテッド アポトーシスおよび関連した状態の処置方法
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
WO1998009523A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11246434A (ja) * 1998-02-25 1999-09-14 Sumitomo Pharmaceut Co Ltd ｂａｘの低下及び／又はｂｃｌ−２の増加誘導剤
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
JP4627356B2 (ja) * 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
KR100883184B1 (ko) * 2000-12-11 2009-02-12 암젠 인코포레이션 Ｃｘｃｒ3 길항제
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
JPWO2003014727A1 (ja) * 2001-08-08 2004-11-25 中外製薬株式会社 心疾患治療剤
CA2472680A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US9101575B2 (en) 2015-08-11
US7838562B2 (en) 2010-11-23
JP2007523858A (ja) 2007-08-23
EP1643983A2 (en) 2006-04-12
AU2004253473B2 (en) 2010-03-04
CN101518524A (zh) 2009-09-02
JP2014088421A (ja) 2014-05-15
CA2778126A1 (en) 2005-01-13
ATE466572T1 (de) 2010-05-15
PL1643983T3 (pl) 2010-10-29
CN100431534C (zh) 2008-11-12
CA2778309C (en) 2014-12-02
US20150283154A1 (en) 2015-10-08
EP1643983B1 (en) 2010-05-05
US20080039530A1 (en) 2008-02-14
CA2778309A1 (en) 2005-01-13
PT1643983E (pt) 2010-06-18
AU2004253473A1 (en) 2005-01-13
MXPA05014216A (es) 2006-03-13
CA2529318C (en) 2013-09-17
CN1826104A (zh) 2006-08-30
DE602004027045D1 (de) 2010-06-17
US20110015159A1 (en) 2011-01-20
WO2005002559A2 (en) 2005-01-13
ES2342396T3 (es) 2010-07-06
WO2005002559A3 (en) 2005-04-14
CA2529318A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
BRPI0411831A (pt) métodos de inibição da permeabilidade vascular e apoptose
AR123240A2 (es) SAL DICLORHÍDRICA O DIBENCENSULFÓNICA DE 2-FLUORO-N-METIL-4-[7-(QUINOLIN-6-ILMETIL)IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-IL]BENZAMIDA, O HIDRATOS O SOLVATOS DE LAS MISMAS; COMPOSICIÓN; MÉTODOS PARA INHIBIR LA ACTIVIDAD DE UNA TIROSINA QUINASA RECEPTORA, LA VÍA DE SEÑALIZACIÓN DE QUINASA HGF / c-MET EN CÉLULAS, LA ACTIVIDAD PROLIFERATIVA DE CÉLULAS, EL CRECIMIENTO TUMORAL EN PACIENTES, LA METÁSTASIS TUMORAL EN UN PACIENTE; MÉTODO PARA TRATAR UNA ENFERMEDAD ASOCIADA CON LA DESREGULACIÓN DE LA VÍA DE SEÑALIZACIÓN DE HGF / c-MET EN PACIENTES, CÁNCER EN PACIENTES; PROCESO PARA PREPARAR DICHOS HIDRATOS Y DICHAS SALES; Y COMPUESTOS RELACIONADOS
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
UA98629C2 (ru) Соединения и способ модуляции киназ
UA111933C2 (uk) Піролопіридини як інгібітори кінази
EA201000130A1 (ru) Бициклические гетероарильные соединения и их применение в качестве ингибиторов киназы
WO2008060907A3 (en) Pyrrolo-pyridine kinase inhibitors
ATE554725T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
WO2007136790A3 (en) Intracellular kinase inhibitors
EA200802213A1 (ru) Способы лечения заболеваний крови
ATE530142T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
EA200901486A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
EA201001331A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
MX2007007588A (es) Analogos de tetrahidroquinolina como agonistas muscarinicos.
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
PA8680201A1 (es) Proceso de elaboración para tigeciclina
WO2008028141A3 (en) Raf inhibitor compounds and methods of use thereof
EA201100255A1 (ru) 5-алкинилпиримидины
EA200702253A1 (ru) Фармацевтическая композиция

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]